Notizie dei mercati

Amylyx Pharmaceuticals, Inc.: per Goldman Sachs il titolo e Neutral

This content has been archived. It may no longer be relevant

Amylyx Pharmaceuticals, Inc.: per Goldman Sachs il titolo e Neutral

Amylyx Pharmaceuticals Goldman


FIMA2681# 2022-08-15T17:01:12+02:00

Show More